tiprankstipranks
Trending News
More News >
Nihon Chouzai Co (JP:3341)
:3341

Nihon Chouzai Co (3341) AI Stock Analysis

Compare
0 Followers

Top Page

JP

Nihon Chouzai Co

(OTC:3341)

Rating:64Neutral
Price Target:
¥3,520.00
▲(12.28%Upside)
Nihon Chouzai Co's stock score is driven by strong technical momentum, though it faces valuation concerns with a high P/E ratio. Financial performance shows healthy revenue growth but declining profitability, impacting the overall score negatively.

Nihon Chouzai Co (3341) vs. iShares MSCI Japan ETF (EWJ)

Nihon Chouzai Co Business Overview & Revenue Model

Company DescriptionNihon Chouzai Co., Ltd. is a leading pharmaceutical company in Japan, specializing in the operation of dispensing pharmacies, the sale of generic drugs, and the provision of healthcare-related services. The company operates through its primary segments, which include the Dispensing Pharmacy Business, the Pharmaceutical Manufacturing and Sales Business, and the Medical Professional Staffing and Placement Business. Nihon Chouzai is dedicated to enhancing healthcare by providing high-quality pharmaceuticals and comprehensive pharmacy services to its customers.
How the Company Makes MoneyNihon Chouzai generates revenue primarily through its Dispensing Pharmacy Business, where it operates a network of pharmacies across Japan, dispensing prescription medications to patients. This segment is the core revenue driver, benefiting from Japan's universal healthcare system and the demand for pharmaceutical services. Additionally, the company manufactures and sells generic drugs, contributing to its revenue through its Pharmaceutical Manufacturing and Sales Business. This segment leverages the growing acceptance and demand for cost-effective generic medications. Furthermore, Nihon Chouzai offers staffing and placement services for medical professionals, providing healthcare institutions with skilled personnel, which adds an additional revenue stream. Key factors contributing to its earnings include strategic partnerships with healthcare providers, government healthcare policies promoting generic drug use, and its expansive pharmacy network.

Nihon Chouzai Co Financial Statement Overview

Summary
Nihon Chouzai Co shows strong revenue growth but faces declining profitability margins. The balance sheet is stable with manageable debt, but cash flow management is challenged by a decline in free cash flow.
Income Statement
65
Positive
The income statement reflects moderate performance with some areas of concern. Gross profit margin and EBIT margin have decreased slightly over the past year, indicating pressure on profitability. Net profit margin has also decreased, but the company shows a strong revenue growth rate of 5.93% over the past year, suggesting healthy top-line growth. However, the decline in EBITDA margin suggests rising operational costs.
Balance Sheet
70
Positive
The balance sheet shows a strong equity position and moderate leverage. The debt-to-equity ratio is reasonable, indicating manageable debt levels. Return on equity has decreased, reflecting reduced profitability relative to equity. However, the equity ratio is strong, highlighting a stable capital structure.
Cash Flow
58
Neutral
The cash flow statement shows challenges in maintaining free cash flow, with a decline from the previous year. The operating cash flow to net income ratio is robust, indicating good cash generation from operations. However, free cash flow to net income ratio has weakened, suggesting higher capital expenditures that could strain liquidity.
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue355.98B360.51B340.31B313.32B299.39B278.95B
Gross Profit57.43B57.37B57.24B53.64B52.42B49.37B
EBITDA12.19B12.97B14.65B16.93B15.05B15.13B
Net Income-599.00M1.39B2.55B4.46B3.71B3.54B
Balance Sheet
Total Assets201.49B197.10B195.09B185.30B178.75B186.26B
Cash, Cash Equivalents and Short-Term Investments21.85B27.46B26.03B23.77B25.54B32.89B
Total Debt59.77B58.27B54.92B58.13B56.17B72.33B
Total Liabilities143.32B138.00B136.74B128.81B125.88B136.39B
Stockholders Equity58.17B59.10B58.35B56.48B52.88B49.87B
Cash Flow
Free Cash Flow0.002.45B10.02B-223.00M11.70B4.68B
Operating Cash Flow0.008.82B20.42B7.53B19.41B11.21B
Investing Cash Flow0.00-9.92B-13.73B-10.02B-9.31B-7.77B
Financing Cash Flow0.002.53B-4.43B713.00M-17.45B-2.81B

Nihon Chouzai Co Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price3135.00
Price Trends
50DMA
3133.62
Positive
100DMA
2376.91
Positive
200DMA
1871.17
Positive
Market Momentum
MACD
14.33
Positive
RSI
48.91
Neutral
STOCH
26.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3341, the sentiment is Neutral. The current price of 3135 is below the 20-day moving average (MA) of 3204.25, above the 50-day MA of 3133.62, and above the 200-day MA of 1871.17, indicating a neutral trend. The MACD of 14.33 indicates Positive momentum. The RSI at 48.91 is Neutral, neither overbought nor oversold. The STOCH value of 26.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:3341.

Nihon Chouzai Co Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
¥202.30B14.55
2.15%8.98%0.10%
76
Outperform
¥419.75B22.77
0.35%14.79%35.84%
74
Outperform
¥539.68B35.83
1.42%5.56%-43.50%
74
Outperform
$523.12B17.0211.61%2.90%6.66%5.56%
71
Outperform
$545.37B24.994.93%4.00%4.63%-47.30%
64
Neutral
¥90.87B67.372.35%0.80%5.94%-45.43%
52
Neutral
$7.45B0.30-61.93%2.28%16.62%1.04%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:3341
Nihon Chouzai Co
3,135.00
1,665.26
113.30%
JP:3141
Welcia Holdings Co., Ltd.
2,588.00
780.86
43.21%
JP:3148
Create SD Holdings Co., Ltd.
3,200.00
-45.47
-1.40%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
3,974.00
1,084.95
37.55%
JP:9989
Sundrug Co
4,590.00
754.31
19.67%
JP:3391
TSURUHA Holdings
11,470.00
2,609.06
29.44%

Nihon Chouzai Co Corporate Events

Nihon Chouzai Reinforces Minority Shareholder Protections Amidst Strong Control
Jun 26, 2025

Nihon Chouzai Co., Ltd. has detailed its controlling shareholders, Yosuke Mitsuhara and Hiroshi Mitsuhara, who collectively hold 62.23% of voting rights. The company emphasizes its commitment to protecting minority shareholders by ensuring that related party transactions are reviewed and approved by the Board of Directors, with legal checks in place to safeguard common interests.

Nihon Chouzai Announces Corrections to Financial Results
Jun 24, 2025

Nihon Chouzai Co., Ltd. announced corrections to its consolidated financial results for the fiscal year ending March 31, 2025, due to errors found during the preparation of their Annual Securities Report. These corrections primarily affect segment-related financial data, including net sales, segment profit, and asset adjustments, which are crucial for stakeholders to assess the company’s financial health and operational efficiency.

Nihon Chouzai Announces Leadership Change for Strategic Growth
May 21, 2025

Nihon Chouzai Co., Ltd. has announced a change in its representative directors to strengthen its management and increase corporate value. Kazunori Ogi will take over as President and Representative Director, succeeding Naoto Kasai. This leadership change is part of the company’s strategy for medium- to long-term growth and continued contribution to the healthcare sector in Japan.

Nihon Chouzai Revises Financial Results and Forecasts
May 21, 2025

Nihon Chouzai Co., Ltd. announced corrections to its previously released consolidated financial results for the fiscal year ended March 31, 2025, and its operations forecast for the fiscal year ending March 31, 2026. The corrections involve adjustments to the EBITDA figures, impacting the company’s financial projections and potentially affecting stakeholder expectations.

Nihon Chouzai Reports Fiscal Year 2025 Financial Results with Plans for Recovery
Apr 30, 2025

Nihon Chouzai Co., Ltd. reported its consolidated financial results for the fiscal year ended March 31, 2025, showing a 5.9% increase in net sales to 360,512 million yen. However, the company experienced declines in EBITDA, operating profit, and ordinary profit, with a significant drop in profit attributable to owners of the parent by 45.5%. Despite these challenges, the company maintained its dividend per share at 25 yen, reflecting a commitment to shareholder returns. The financial outlook for the next fiscal year anticipates modest growth in net sales and a substantial increase in profit attributable to owners of the parent by 151.6%, indicating a potential recovery and strategic adjustments to improve profitability.

Nihon Chouzai Reports Extraordinary Losses and Earnings Shortfall for FY 2025
Apr 30, 2025

Nihon Chouzai Co., Ltd. announced significant extraordinary losses for the fiscal year ending March 31, 2025, due to impairment losses in its Dispensing Pharmacy Business, totaling 4,132 million yen. The company also reported a shortfall in its consolidated earnings compared to its forecast, attributed to lower prescription volumes and manufacturing issues at its Kawauchi Plant, impacting sales and profitability.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 05, 2025